阿法骨化醇对高血压颈动脉粥样硬化患者血尿酸、C反应蛋白和补体的影响

The effect of Alfacalcidol on the serum levels of CRP,BUA and complement in patients with hypertension and carotid artherosclerosis

目的观察阿法骨化醇对老年高血压合并颈动脉粥样硬化(CAS)患者血尿酸(BUA)、补体和血清C-反应蛋白(CRP)水平的影响。方法随机选择122例老年高血压合并CAS患者分为2组。治疗组:65例口服阿法骨化醇加常规药物治疗3个月。对照组:57例接受常规药物治疗3月。比较治疗前后患者的血压、血糖、血脂、肾功能、CRP、C3、C4和BUA值变化。结果治疗组治疗后CRP、C3和BUA的测定值明显低于治疗前水平(P<0.05);对照组治疗前后CRP、C3和BUA的测定值差异无统计学意义(P>0.05)。结论阿法骨化醇能够降低老年高血压病合并CAS患者的CRP、C3和BUA水平,可能对防治动脉粥样硬化有着积极的作用。

Objective To observe the effect of Alfacalcidol on the levels of C-reactive protein （CRP）, C3 and blood uric acid （BUA） in serum of elderly patients with hypertension and carotid artherosclerosis. Methods 122 elderly patients with hypertension and carotid artherosclerosis were divided into two groups. The 65 patients in treatment group were treated with Alfacalcidol and routine drugs,while the other 57 patients in control group were treated with routine drugs only. The levels of blood calcium, blood phosphonium, CRP, C3 and BUA, renal function before and after treatment were detected. The results were compared before treatment and after treatment. Results In treatment group, the levels of CRP, C3 and BUA after treatment were significantly lower than those before treatment （ P 〈 0.05 ）. But there were no significant differences in these parameters in control group （ P 〉 0.05 ）. Conclusion Alfacalcidol can decrease the levels of CRP, C3 and BUA in elderly patients with hypertension and carotid artherosclerosis, which has positive effect in early prevention and therapy of artherosclerosis.